Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Beating Scholastic Difficulties: Understudy Examples of overcoming adversity - 2Figurine of a woman and a goose offers peek at prehistoric beliefs
- 3Experience Is standing by: History's Most noteworthy Travelers
- 4Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D.
- 5‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Director Emerald Fennell explains why "Wuthering Heights" has quotation marks around the title
- Merz says army could be involved in mine-clearing from Hormuz
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- At least 7 dead as Israel renews attacks on Beirut and across Lebanon
- Partake in the Outside: Senior-Accommodating Exercises for 2024
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Wait, it's 'Harry Potter and the Philosopher's Stone'? Why the new HBO series name is significant to Americans
- Israeli military says it hit dozens of military facilities in Tehran
